L-carnitine for Type 2 Diabetes Type 2 diabetes is a chronic disease characterised by insulin resistance and poor glucose metabolism
How sublingual tirzepatide works differently from injections Before touching a single number on the dosage chart, you need to understand why sublingual dosing exists as its own category
GLP-1 drugs mimic the action of a hormone called glucagon-like peptide 1, a natural hormone produced by the body in the gut
Residents of other countries must refer to respective laws
Postmenopausal women face additional risk due to estrogen deficiency affecting urogenital tissue
GLP-1 Receptor Agonist Market Report 2026 Global Outlook By Drug Class (Exenatide, Liraglutide, Dulaglutide, Lixisenatide, Other Drugs), By Route Of Administration (Parenteral, Oral), By End Users (Hospitals, Surgical Clinics, Other Users) Market Size, Trends, Strategies, and Forecast to 2035 GLP-1 Receptor Agonist Market Overview GLP-1 Receptor Agonist market size has reached to $14.09 billion in 2025 Expected to grow to $18.32 billion in 2030 at a compound annual growth rate (CAGR) of 5.4% Growth Driver: Surging Diabetes Cases Fuel Growth In Glp-1 Receptor Agonist Market Market Trend: Sustained-Release Glp-1 Receptor Agonists Are Gaining Popularity North America was the largest region in 2025 and Asia-Pacific is the fastest growing region